Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine candidate, head-to-head versus Shingrix in participants aged 50 to 69 years on Thursday.
In Part 1 of the trial, at one month after the second vaccine dose, Z-1018 demonstrated antibody and CD4⁺ T cell vaccine responses similar to those observed in the comparator arm receiving GSK Plc’s (NYSE:GSK) Shingrix, the currently licensed shingles vaccine, with a favorable tolerability profile. In the second quarter of 2025, Shingrix sales reached 853 million pounds, up 3% year-over-year.
